Pre-made Tilavonemab biosimilar ( Whole mAb, anti-MAPT therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-572
Anti-MAPT therapeutic antibody (Pre-made Tilavonemab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tilavonemab (formerly C2N 8E12) is a humanised recombinant anti-human tau monoclonal antibody, being developed by AbbVie and C2N Diagnostics for the treatment of various neurological disorders including Alzheimer's disease.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MAPT therapeutic antibody (Pre-made Tilavonemab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Alzheimer's disease;Progressive supranuclear palsy|